Lindsey K Sablatura

Aug 29, 2024 | digitalcommons.library.tmc.edu | Kristin Bircsak |Peter Shepherd |Madhavi Bathina |Lindsey K Sablatura

AbstractMany advanced cancer models, such as patient-derived xenografts (PDXs), offer significant benefits in their preservation of the native tumor's heterogeneity and susceptibility to treatments, but face significant barriers to use in their reliance on a rodent host for propagation and screening. PDXs remain difficult to implement in vitro, particularly in configurations that enable both detailed cellular analysis and high-throughput screening (HTS).